Skip to main content
Professional Technical IVT

Secretory Carcinoma

Also written as: SC — Secretory Carcinoma

A low-grade salivary gland malignancy defined by ETV6-NTRK3 gene fusion, formerly known as mammary analogue secretory carcinoma (MASC).

Full Definition

Secretory carcinoma (SC) was formerly termed mammary analogue secretory carcinoma (MASC) because of its morphological and molecular resemblance to secretory carcinoma of the breast, sharing the pathognomonic ETV6-NTRK3 gene fusion. In 2017, the WHO reclassified it as simply 'secretory carcinoma' to reflect its salivary gland identity. Histologically, it shows microcystic, tubular, and solid growth patterns with eosinophilic, bubbly secretory material. Editors must update references to 'MASC' in contemporary manuscripts to 'secretory carcinoma' and note that the ETV6-NTRK3 fusion is the defining molecular feature. It should not be confused with acinic cell carcinoma despite morphological overlap.

Usage

Usage note: Flag 'MASC' as a superseded term in manuscripts dated post-2017. Always note the ETV6-NTRK3 fusion when defining this entity.

In Context

  • "Molecular testing confirmed ETV6-NTRK3 fusion, establishing the diagnosis of secretory carcinoma, formerly classified as MASC." — Molecular pathology report
  • "The editor updated 'mammary analogue secretory carcinoma' to 'secretory carcinoma' throughout the manuscript as per current WHO terminology." — Copy-editing note

Also known as

MASC (former term) mammary analogue secretory carcinoma (former term)

Don't confuse with

Acinic Cell Carcinoma Mucoepidermoid Carcinoma

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON